In re Becton Dickinson India Private Limited (CAAR Delhi)
Summary: The Customs Authority for Advance Rulings (CAAR), New Delhi, considered an application filed by Becton Dickinson India Private Limited seeking modification of Advance Ruling No. CAAR/DEL/Becton/43/2026 dated 17 August 2026 concerning the customs classification of the BD Viper LT System, imported for use with the BD Onclarity HPV Assay. The original ruling had classified the product under Customs Tariff Heading (CTH) 9027 but contained observations suggesting that the instrument did not perform chemical analysis and was used in conjunction with in-vitro diagnostic (IVD) assays. The applicant sought correction of these observations, contending that they did not accurately reflect the instrument’s technical functions. The Authority examined the application under Regulation 21 of the Customs Authority for Advance Rulings Regulations, 2021.
The applicant explained that the BD Viper LT System is an automated, real-time molecular diagnostic testing instrument used in clinical laboratories for detecting high-risk Human Papillomavirus (HPV) genotypes. It performs automated nucleic-acid extraction, amplification and detection using the BD Onclarity HPV Assay. According to the applicant, the system does not merely report positive or negative results but analyses the specimen through chemical and biological processes, including DNA extraction, amplification and fluorescence-based detection. The applicant submitted that the original ruling had incorrectly interpreted the product’s operation and overlooked the analytical processes involved in molecular diagnostic testing.
In support of its application, the company relied on the import licence issued under the Medical Devices Rules, 2017, by the Central Drugs Standard Control Organisation (CDSCO), product manuals, technical specifications, United States Food and Drug Administration (US FDA) approval and clinical performance documentation. It explained that the BD Viper LT System processes biological specimens using specialised reagents, identifies target DNA sequences and generates detailed results for different HPV genotypes. The applicant also submitted an expert opinion from Dr. Neerja Bhatla of the All India Institute of Medical Sciences and clinical laboratory reports demonstrating the system’s diagnostic capabilities. These documents were relied upon to establish that the instrument performed analytical functions and was not merely a device for displaying predetermined results.
The applicant further contended that the instrument was independently capable of performing physical or chemical analysis and should therefore fall within Heading 9027 of the First Schedule to the Customs Tariff Act, 1975. It argued that the relevant Harmonised System of Nomenclature (HSN) Explanatory Notes specifically covered instruments and apparatus used in clinical laboratories for in-vitro diagnostic testing. The fact that the BD Viper LT System operated with the BD Onclarity HPV Assay did not alter its essential character as an analytical instrument. The applicant also distinguished Heading 9031, which generally covers measuring or checking instruments not specified elsewhere, and maintained that Heading 9027 provided the more appropriate and specific classification.
The Authority examined the technical material, product literature, laboratory reports and applicant’s additional submissions. It considered the operating mechanism of the BD Viper LT System, including specimen preparation, DNA extraction, amplification and fluorescence-based analysis. The Authority accepted that the instrument performed physical or chemical analysis and observed that its use in clinical laboratories for in-vitro diagnostic testing was consistent with the scope of Heading 9027. It also considered the General Rules for Interpretation of the Customs Tariff and concluded that Heading 9031 was inappropriate because the product was more specifically covered under Heading 9027. Consequently, the Authority determined that the correct eight-digit classification was Customs Tariff Item (CTI) 9027 89 90.
On the applicable customs duties, the Authority held that the BD Viper LT System, classified under CTI 9027 89 90, attracted Basic Customs Duty (BCD) at 7.5% under the First Schedule to the Customs Tariff Act, 1975. It further examined Notification No. 9/2025-Integrated Tax (Rate), dated 17 September 2025, and concluded that the product qualified for Integrated Goods and Services Tax (IGST) at 5% under the relevant entry covering instruments and apparatus for medical, surgical, dental or veterinary uses, including those used for physical or chemical analysis. The Authority rejected the application of the higher 18% IGST entry and held that the applicable tax treatment should be determined by the product’s classification and the specific notification entry.
Accordingly, the Customs Authority for Advance Rulings modified the earlier ruling to recognise the analytical functions of the BD Viper LT System and confirmed its classification under CTI 9027 89 90, with BCD at 7.5% and IGST at 5%. The decision emphasised that customs classification must be based on the actual technical characteristics, operating principles and essential functions of the imported instrument rather than merely on its commercial description or the format in which test results are reported. The ruling provides guidance on the classification of automated molecular diagnostic instruments used in clinical laboratories, particularly where such instruments perform nucleic-acid extraction, amplification and detection in conjunction with diagnostic assays.
Becton Dickinson India Private Limited sought modification of an advance ruling concerning the classification of its BD Viper LT System used with the BD Onclarity HPV Assay. The applicant argued that the system performs automated molecular diagnostic testing, including extraction, amplification and detection of nucleic acids. The Authority examined technical documentation, product manuals, medical-device licensing material and laboratory test reports. It concluded that the instrument performs physical or chemical analysis and falls under Heading 9027 rather than Heading 9031 of the Customs Tariff. The Authority modified the ruling and classified the BD Viper LT System under CTI 9027 89 90, with basic customs duty at 7.5% and IGST at 5%, based on the tariff and notification provisions addressed in the ruling.
In conclusion, the CAAR confirmed that the BD Viper LT System was classifiable under CTI 9027 89 90, attracting 7.5% Basic Customs Duty and 5% IGST under the tariff and notification provisions considered in the ruling. The decision recognised that automated molecular diagnostic equipment performing nucleic-acid extraction, amplification and detection can qualify as apparatus for physical or chemical analysis, notwithstanding its use with an in-vitro diagnostic assay. The ruling is relevant to importers of automated diagnostic and laboratory equipment because it illustrates the significance of technical documentation, product functionality, HSN Explanatory Notes and specific notification entries in determining customs classification and applicable import taxes.
